4Q20 Wrap: Stocking up

Life sciences stocks continued an upward trajectory at the end of 2020, with median gains of at least 7% in 4Q20 and at least 24% over the year across all market cap tiers. Companies valued between $500-$999 million were the best performers during the last quarter with a median gain of 13%. 

Large-cap companies that started the quarter with valuations over $10 billion saw a median gain of 7%, with 24 companies gaining value and 17 losing value. The group was led by Chinese telemedicine company JD Health International Inc. (HKEX:6618), which closed up 113% on the quarter following its Hong Kong IPO in December. ...